logo-loader
viewZelira Therapeutics Ltd

Full interview: Zelira Therapeutics releases interim data for Phase II clinical trial for insomnia

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal cannabis for insomnia.

The trial confirmed that ZLT-101 therapy achieved the primary endpoint of a statistically significant improvement in Insomnia Severity Index scores in patients diagnosed with chronic insomnia.

They talk about the key outcomes, what comes next and why it’s such a major milestone for the company.

Quick facts: Zelira Therapeutics Ltd

Price: 0.037 AUD

ASX:ZLD
Market: ASX
Market Cap: $35.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in...

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC. The deal complements a number of...

on 12/3/19

2 min read